AngioDynamics reports Q1 FY2027 earnings beat and names new CEO Eric Honroth
AngioDynamics announced first‑quarter fiscal 2027 results on Oct. 8, 2026, showing revenue of $80.9 million, up 6.9% year‑over‑year, and an adjusted loss of $0.04 per share, beating consensus estimates of a $0.11 loss. The company also confirmed its full‑year guidance of $336 million‑$341 million revenue and a $0.29‑$0.24 adjusted loss per share. Effective Nov. 2, 2026, Eric Honroth will succeed Jim Clemmer as President and CEO.
Why it matters
The earnings beat demonstrates improving profitability, but the unchanged outlook and modest revenue growth left the stock down in pre‑market trading, according to the company’s press release and analyst commentary. The CEO transition signals continuity in the company’s Med Tech growth strategy, as noted by the company.
Key facts
- 1Quarter ended August 31, 2026, net sales were $80.9 million, a 6.9% YoY increase. stocktitan.net
- 2Adjusted loss per share was $0.04, beating the consensus loss estimate of $0.11 per share. finance.yahoo.com
- 3GAAP net loss was $7.1 million, or $0.17 per share, compared with $10.9 million a year earlier. finance.yahoo.com
- 4Adjusted EBITDA for the quarter was $5.0 million, up from $2.2 million a year earlier. stocktitan.net
- 5Gross margin was 59.4%, an improvement of 410 basis points YoY. stocktitan.net
- 6Med Tech net sales were $39.9 million, up 13.2% YoY. stocktitan.net
Summary written by AlphAI from 20 of 22 sources. Not investment advice. Figures are as stated by the linked sources.